Company Stock Information

Company Stock Data | Company Summary in Chinese | Company Press Release (51) | NAI Interview(0) | Company Event(0) | Research Report (0) | Chinese Micro Site | Contact Company
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)
Show Interactive Chart | Add to Portfolio

Stock Info

Last Trade 13.620
Change 0.190
Change (%) 1.41%
Volume 1,608,727
10 Days Avg Vol 1,224,600
3 Months Avg Vol 103,458,300
52 Weeks Lo/Hi $ 7.51 - $ 18.18
YTD Price Gain % 83.2%
10 Wks Moving Avg $ 16
200 Days Moving Avg $ 12
Liquidity Ratio 10,363,100
Market Cap 2,591,381,160

Related News

TitleDate
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer07/22/2014
Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme04/08/2014
Halozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH2004/03/2014
Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-50103/24/2014

Summary

Contact Info

Halozyme Therapeutics's address Halozyme Therapeutics
11388 Sorrento Valley Road
San Diego CA 92121
Halozyme Therapeutics's Telephne number +1 858 794-888
Halozyme Therapeutics's fax number +1 858 704-831
Halozyme Therapeutics's email account kgustafson@halozyme.com
Halozyme Therapeutics's web site http://www.halozyme.com
Dr. Helen Torley, MB.Ch.B.